OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
The order this company entered each market — oldest to newest
Sign up to see the full signal feed
How OrbiMed's international expansion compares to its competitors
OrbiMedYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 OrbiMedYou | 0 | 0 | 0% | 0 | 26 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
HanchorBio completed bookbuilding for Taiwan Innovation Board IPO at NT$120 per share, introducing OrbiMed as strategic investor. The biotech company issued 9.4 million shares and expects listing on May 29, 2026.
Haisco Pharmaceutical licenses global rights for HSK39004, a dual PDE3/4 inhibitor for COPD, to AirNexis for up to $1.063 billion, marking a breakthrough in Chinese respiratory innovation.
FDA grants Fast Track Designation to OnCusp Therapeutics' CUSP06 for platinum-resistant ovarian cancer treatment, accelerating development of promising therapy.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about OrbiMed's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
